Sigilon Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 43.56 million compared to USD 77.31 million a year ago. Basic loss per share from continuing operations was USD 17.42 compared to USD 31.59 a year ago.
Sigilon Therapeutics, Inc.
Equities
SGTX
US82657L2060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |